Company Overview and News

1
TDG / Transdigm Group, Inc. 8-K (Current Report)

2018-06-18 sec.gov
Document UNITED STATES
TDG

1
TDG / Transdigm Group, Inc. FORM 8-K (Current Report)

2018-05-31 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
TDG

21
Transdigm (TDG) Up 6% Since Earnings Report: Can It Continue?

2018-05-31 zacks
It has been about a month since the last earnings report for Transdigm Group Incorporated (TDG - Free Report) . Shares have added about 6% in that time frame.
IMMR ALIMR TDG STX SU SU

1
TDG / Transdigm Group, Inc. SD

2018-05-30 sec.gov
Document UNITED STATES
TDG

8
Here's Why Adding TransDigm to Your Portfolio Makes Sense

2018-05-28 zacks
TransDigm Group Incorporated (TDG - Free Report) managed to impress investors with its recent earnings streak as the company’s bottom line trumped estimates thrice in the trailing four quarters. We believe that the company’s strong operational efficiency, its solid portfolio of products as well as complementary acquisitions will continue to be key growth drivers, going forward.
DUKH CVU TDG DUK AVAV NMIH KLXI

7
Is Guggenheim S&P 500 Equal Weight Industrials ETF (RGI) a Hot ETF Right Now?

2018-05-21 zacks
The Guggenheim S&P 500 Equal Weight Industrials ETF (RGI - Free Report) made its debut on 11/01/2006, and is a smart beta exchange traded fund that provides broad exposure to the Industrials ETFs category of the U.S. equity market.
RGI TDG CSX TXT VIS CSIQ

5
Is Guggenheim S&P 500 Equal Weight Industrials ETF (RGI) a Hot ETF Right Now?

2018-05-17 zacks
A smart beta exchange traded fund, the Guggenheim S&P 500 Equal Weight Industrials ETF (RGI - Free Report) debuted on 11/01/2006, and offers broad exposure to the Industrials ETFs category of the U.S. equity market.
RGI TDG CSX TXT VIS

1
TDG / Transdigm Group, Inc. FORM 8-K (Current Report)

2018-05-14 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
TDG

63
Defense Stocks Rally on Iran Deal: 4 Hot Picks

2018-05-11 zacks
In a not so surprising move on May 8, the United States withdrew from the historic deal designed to contain Iran’s nuclear program. Further, a spate of other sanctions is likely to be slapped on the Middle Eastern country. President Trump has characterized the Iran nuclear agreement as a “horrible one-sided deal that should have never, ever been made.”
LMT NOC GD TDG BOE BA

2
Esterline Looks Past Kirkhill To New Multiyear Opportunity

2018-05-11 aviationweek
Leaders of specialty products provider Esterline Technologies, which provides components for a number of commercial aircraft programs, have indicated they do not see other immediate troubled assets that should be sold off as the company recently did with the Kirkhill elastomers unit to TransDigm Group. But Esterline executives still sound open to divestitures. “As far as problem areas, I wouldn’t say there is something that is in that realm of it’s taking a lot of time and .
TDG ESL

1
TDG / Transdigm Group, Inc. FORM 8-K (Current Report)

2018-05-08 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
TDG

2
Esterline Looks Past Kirkhill To New Multiyear Opportunity

2018-05-04 aviationweek
Leaders of specialty products provider Esterline Technologies, which provides components for a number of commercial aircraft programs, have indicated they do not see other immediate troubled assets that should be sold off as the company recently did with the Kirkhill elastomers unit to TransDigm Group. But Esterline executives still sound open to divestitures. “As far as problem areas, I wouldn’t say there is something that is in that realm of it’s taking a lot of time and .
TDG ESL

1
TDG / Transdigm Group, Inc. 10-Q (Quarterly Report)

2018-05-04 sec.gov
Document Table of Contents UNITED STATES
TDG

1
TDG / Transdigm Group, Inc. FORM 8-K (Current Report)

2018-05-03 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
TDG

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 893641100